Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, C-IV has been approved by the U.S. FDA and is under review in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
In addition, the company has two late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.
FINTEPLA will be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program, and is expected to be available through Zogenix’s specialty pharmacy partner Anovo.
Anova will convey this prescription to the appropriate dispensing pharmacy; verify the patient’s insurance coverage for FINTEPLA; provide information regarding payer coverage and benefits and how to prepare prior authorization requests, coverage determination appeals, or other coverage issues; and provide educational and support services associated with FINTEPLA.
Anovo was founded in 2012 and is focused on being the patients’, physicians’ and pharmaceutical companies’ premier source for customized treatment and support programs that address the unique needs of patients with certain complex, costly and chronic diseases.
Takeaway: Anova offers personalized, high-touch specialty pharmacy services where patients, physicians and their staff get to deal directly with pharmacists and customer care staff